Study finds that patients with cancer and a suppressed immune system are at high risk for severe COVID if treated with systemic drug therapies

Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven’t received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.

Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines, According to JNCCN Study

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

NCCN Updates Recommendations for COVID-19 Vaccination with Information on Bivalent Vaccines, Children with Cancer, and Other Developments

National Comprehensive Cancer Network Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis details clarified expert consensus to help guide providers on latest data and information, available at NCCN.org/covid-19.

Cancer Guidelines Organization Supports Mandatory COVID-19 Vaccination for Health Workers

National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee calls for healthcare workforce vaccine requirements to assure healthcare community is doing all it can to prevent exposure to COVID-19.

Study of Cancer Patients and COVID-19 Highlights Health Disparities

Findings from a study led by researchers at Henry Ford Cancer Institute, in collaboration with Advocate Aurora Health, the Food and Drug Administration and Syapse®, show an elevated risk for severe COVID-19 effects or death among patients with cancer, with the highest risk being among low-income and Black patients.

Cancer Organizations Urge Priority Access to COVID-19 Vaccine for Cancer Patients, Survivors

130 cancer centers and other cancer organizations sent a letter to President Joseph R. Biden, key members of his administration, and leading state public health officials to strongly encourage prioritizing patients with cancer and survivors of cancer when administering lifesaving COVID-19 vaccines.

NCCN Shares New Guidance Principles for Vaccinating People with Cancer Against COVID-19

The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.

AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health

AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.

AACI Applauds Approval of COVID-19 Vaccine, Supports Widespread Vaccination Efforts

The Association of American Cancer Institutes (AACI) commends the U.S. Food and Drug Administration (FDA) for its swift action to grant Emergency Use Authorization (EUA) to Pfizer’s COVID-19 vaccine.

Newly diagnosed cancer patients, African Americans more at risk for COVID-19 infection

Cancer patients, especially newly diagnosed and African American patients, are significantly at risk for COVID-19 infection, hospitalization and mortality, according to a new study published in JAMA Oncology by researchers from Case Western Reserve University School of Medicine and the Case Comprehensive Cancer Center.

AACI Urges President Trump to Share Key COVID-19 Information With Biden Transition Team

In a November 20 letter, the Association of American Cancer Institutes (AACI) called on the Trump administration to share vital information about its coronavirus response with President-elect Joe Biden and his transition team.

Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma

Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.